background
alphamomorcharin
momordica
antihiv
protein
deriv
momordica
charantia
l
confirm
possess
antitumor
antiviru
activ
due
rnanglycosidas
activ
howev
strong
immunogen
short
plasma
halflif
limit
clinic
applic
solv
problem
two
protein
modifi
mpeg
lysnh
kda
methodologyprincip
find
articl
novel
purif
strategi
two
main
type
ribosomeinactiv
protein
rip
success
develop
laboratoryscal
prepar
use
dramat
method
mg
mg
obtain
one
purif
process
g
momordica
charantia
seed
homogen
properti
two
protein
assess
gradient
sdspage
electrospray
ioniz
quadrupl
mass
spectrometri
ntermin
sequenc
analysi
well
western
blot
two
polyethylen
glycol
peg
ylate
protein
synthes
purifi
homogen
mono
di
tripegyl
protein
character
matrixassist
laser
desorpt
ionizationtim
flight
mass
spectrometri
analysi
antitumor
antiviru
activ
indic
serial
pegyl
rip
preserv
moder
activ
jar
choriocarcinoma
cell
herp
simplex
furthermor
pegyl
protein
show
antitumor
antiviru
activ
time
decreas
immunogen
compar
unmodifi
counterpart
conclusionsignific
obtain
novel
purif
strategi
meet
requir
larg
amount
sampl
research
chemic
modif
solv
problem
strong
immunogen
meanwhil
preserv
moder
activ
find
suggest
potenti
applic
pegyl
pegyl
antitumor
antiviru
agent
accord
result
pegyl
rip
construct
nanomateri
target
drug
decreas
immunogen
side
effect
nanotechnolog
make
lowreleas
drug
prolong
halflif
period
human
bodi
momordica
charantia
l
mc
momordica
linn
genu
famili
cucurbitacea
commonli
known
bitter
melon
tradit
medicin
plant
indigen
china
fruit
seed
extract
mc
use
china
centuri
antiviru
antitumor
immunopotenti
agent
purpos
recent
year
sever
ribosomeinactiv
protein
rip
includ
momordica
antihiv
protein
mmc
group
belong
famili
singlechain
rip
found
abil
inhibit
protein
biosynthesi
tumor
cell
catalyt
inactiv
ribosom
subunit
protein
also
found
abl
inhibit
multipl
herp
simplex
polioviru
cell
acquir
human
immunodefici
viru
typel
hivl
howev
strong
immunogen
allerg
reaction
short
halflif
protein
consid
major
barrier
applic
therapeut
agent
vivo
recent
year
research
shift
focu
technolog
establish
technolog
polyethylen
glycol
peg
conjug
pegyl
bestow
protein
sever
benefit
increas
plasma
halflif
decreas
toxic
reduc
immunogen
antigen
food
drug
administr
approv
pegyl
form
therapeut
protein
uricas
erythropoietin
granulocytecoloni
stimul
factor
interferon
adenosin
deaminas
asparaginas
growth
hormon
antagonist
anoth
technolog
nanotechnolog
use
nanomateri
pack
potenti
therapeut
protein
extend
halflif
period
make
target
drug
potenti
therapeut
protein
possess
biolog
activ
inhibit
protein
biosynthesi
ribosom
inactiv
antitumor
antiviru
especi
antihiv
replic
howev
foreign
protein
like
potenti
therapeut
protein
poor
biocompat
limit
develop
applic
overcom
problem
studi
first
purifi
two
main
protein
bitter
melon
seed
carri
pegyl
use
branch
kda
mpeg
lysnh
direct
specif
lysil
group
homogen
onem
twomer
threemer
pegrip
identifi
matrixassist
laser
desorpt
ionizationtim
flight
mass
spectrometri
malditofm
immunogen
vivo
remark
decreas
also
importantli
antitumor
antiviru
activ
vitro
moder
influenc
compar
unpegyl
counterpart
work
begin
step
toward
use
clinic
applic
pegyl
nanotechnolgi
may
indic
potenti
applic
develop
antitumor
antiviru
agent
futur
bitter
melon
seed
obtain
institut
agricultur
scienc
techniqu
sichuan
provinc
china
matric
electrophoresi
product
sigmaaldrich
st
loui
mo
biorad
laboratori
hercul
ca
spsepharos
ff
sephacryl
macrocapsp
ampholyt
purchas
amersham
pharmacia
biotech
piscataway
nj
mpeg
lysnh
kda
obtain
shearwat
polym
huntsvil
al
dulbecco
modifi
eagl
medium
dmem
fetal
bovin
serum
use
cell
cultur
gibco
brl
grand
island
ne
dna
purchas
takara
dalian
china
nitrocellulos
nc
membran
obtain
biorad
laboratori
sheepantimous
ablink
alkalin
phosphatas
purchas
sigmaaldrich
jar
choriocarcinoma
cell
purchas
cell
bank
shanghai
institut
cell
biolog
shanghai
china
step
tri
either
alon
combin
within
process
purif
carri
unless
specif
state
firstli
powder
fresh
bitter
melon
seed
extract
nacl
solut
ph
solut
adjust
simpl
centrifug
supernat
neutral
fraction
ammonium
sulfat
precipit
dialyz
ph
phosphat
buffer
secondli
sampl
appli
onto
spsepharos
ff
column
elut
ph
phosphat
buffer
contain
nacl
elut
peak
contain
kda
protein
collect
thirdli
portion
load
onto
sephacryl
column
elut
peak
kda
protein
pool
final
sampl
appli
onto
macrocapsp
column
linear
gradient
nacl
ph
mm
sodium
phosphat
buffer
elut
column
two
peak
kda
protein
respect
collect
briefli
separ
sdspage
transfer
nc
membran
nonspecif
bind
block
wash
place
membran
solut
bsa
nc
membran
incub
mous
mcab
expos
sheepantimous
ab
link
alkalin
phosphatas
ad
bcip
phosphat
color
band
visual
photograph
analysi
nc
membran
incub
dilut
solut
rat
pcab
gentl
agit
condit
gener
pegyl
pegyl
obtain
follow
optim
condit
mgml
react
mpeg
lysnh
mass
ratio
peg
rip
ph
mm
borat
buffer
room
temperatur
minut
reaction
mixtur
appli
sephacryl
column
pegyl
conjug
collect
assess
gradient
sdspage
malditofm
topolog
inactiv
activ
accord
previous
describ
method
antitumor
activ
vitro
jar
choriocarcinoma
cell
maintain
incub
suppli
humidifi
atmospher
co
cultur
medium
dmem
contain
mm
hepe
fetal
bovin
serum
cell
viabil
prolifer
determin
quantit
bromid
mtt
total
cellsml
appli
microtit
plate
per
well
expos
pegyl
pegyl
unpegyl
counterpart
mgml
hour
cell
without
drug
use
control
concentr
test
quadrupl
determin
procedur
carri
accord
previou
descript
optic
densiti
od
nm
measur
use
elisa
plate
reader
el
biotek
atlanta
ga
cell
viabil
prolifer
observ
togeth
control
inhibitori
effect
pegyl
rip
herp
simplex
vero
cell
cultur
logarithm
growth
phase
ml
dmem
contain
vv
fetal
bovin
serum
penicillin
uml
streptomycin
remov
medium
cell
substitut
ml
medium
infect
herp
simplex
hour
ml
mainten
medium
contain
vv
fetal
bovin
serum
penicillin
uml
streptomycin
ad
cell
continu
cultur
day
cell
appear
cytopath
effect
cpe
infect
supernat
collect
test
viru
titer
determin
viru
titer
vero
cell
cellsml
appli
per
well
microtit
plate
cultur
hour
discard
medium
infect
supernat
dilut
medium
ad
well
quadrupl
cpe
increas
tcid
percent
tissu
cultur
infect
dose
calcul
accord
reed
muench
measur
cytotox
cytotox
pegyl
pegyl
evalu
quantit
mtt
test
total
vero
cellsml
appli
microtit
plate
per
well
expos
unpegyl
protein
pegylatedprotein
l
nmol
l
mg
l
mg
l
acyclovir
acv
l
l
hour
well
cell
without
drug
control
concentr
test
quadrupl
determin
procedur
carri
accord
previou
descript
od
nm
measur
use
elisa
inhibit
protein
antigen
secret
total
vero
cellsml
seed
plate
mlwell
incub
co
hour
abandon
supernat
stock
solut
tcid
ml
ad
well
incub
hour
cultur
medium
contain
protein
concentr
mention
previous
cytotox
method
ad
well
neg
posit
cell
control
establish
incub
hour
antigen
cultur
supernat
test
human
antigen
enzymelink
immunosorb
assay
kit
indirect
elisa
analysi
viru
inactiv
vero
cell
infect
ad
mgml
mtt
well
incub
hour
dmso
ad
well
od
read
micropl
spectrophotomet
percentag
inhibit
calcul
formula
describ
head
measur
cytotox
fifti
spragu
dawley
rat
randomli
classifi
control
pegyl
pegyl
group
ten
rat
control
group
subcutan
inject
salin
solut
rip
pegyl
rip
group
emulsifi
freund
complet
adjuv
dose
mgkg
infect
frequenc
day
day
blood
sampl
collect
capillari
vessel
rat
eye
separ
sera
store
antigenspecif
serum
igg
level
measur
elisa
briefli
plate
coat
purifi
antigen
rip
pegrip
carbonateco
buffer
spss
statist
softwar
spss
inc
chicago
il
use
analysi
p
consid
statist
signific
purif
identif
purif
perform
appli
ammonium
sulfat
precipit
acidif
spsepharos
ff
sephacryl
macrocapsp
chromatographi
conclus
mg
mg
recoveri
respect
obtain
g
start
materi
seed
procedur
purif
summar
tabl
optim
pegyl
reaction
high
total
pegyl
ratio
obtain
gradient
sdspage
monitor
figur
show
unpegyl
counterpart
reaction
mixtur
success
remov
sephacryl
chromatographi
superdex
chromatographi
malditofm
analysi
figur
onem
twomer
threemer
pegyl
isom
da
da
da
molar
ratio
mpeg
lysnh
detect
conjug
meanwhil
onem
twomer
pegyl
isom
da
da
molar
ratio
mpeg
lysnh
found
conjug
demonstr
topolog
inactiv
activ
supercoil
dna
incub
pegyl
rip
unpegyl
counterpart
suitabl
enzymat
digest
condit
experi
sampl
cleav
supercoil
doublestrand
dna
produc
nick
circular
linear
dna
shown
figur
exhibit
dnaselik
activ
investig
effect
pegyl
pegyl
cell
viabil
prolifer
jar
cell
seed
plate
treat
increas
concentr
pegyl
rip
unpegyl
counterpart
hour
figur
differ
time
mgml
figur
statist
analysi
reveal
concentr
mgml
start
significantli
reduc
prolifer
cell
hour
incub
analys
result
figur
promin
hour
treatment
continu
incub
hour
protein
enhanc
cytotox
cell
pegyl
induc
alter
morpholog
jar
cell
figur
process
hour
untreat
jar
cell
extend
flatten
figur
treat
group
show
fewer
cell
abnorm
shape
shrinkag
bleb
loss
membran
asymmetri
indic
cytotox
effect
modifi
jar
cell
particular
group
show
extrem
obviou
morpholog
chang
figur
pegyl
also
show
similar
cytotox
effect
jar
cell
inhibitori
effect
pegyl
pegyl
tcid
calcul
use
method
reed
muench
emerg
cpe
use
posit
sign
cpe
dilut
cytopath
tabul
tabl
measur
cytotox
design
establish
appropri
dose
rang
research
inhibitori
effect
protein
vero
cell
result
figur
reflect
effect
differ
concentr
test
protein
cell
viabil
vero
cell
show
acv
signific
inhibit
vero
cell
test
concentr
rang
cell
viabil
maintain
l
l
therefor
dose
rang
test
protein
inhibit
vero
cell
infect
viru
l
inhibitori
effect
pegyl
acv
glycoprotein
antigen
secret
glycoprotein
test
determin
glycoprotein
antigen
tabl
result
show
dosedepend
inhibitori
effect
ic
l
l
l
l
l
acv
respect
furthermor
ic
lower
gener
drug
acv
dose
inhibitori
effect
glycoprotein
antigen
secret
glycoprotein
higher
higher
mtt
result
show
ratio
cell
viabil
increas
dosedepend
featur
compar
control
group
protein
concentr
higher
l
acv
display
effect
inactiv
dose
ratio
cell
viabil
higher
higher
indic
abil
direct
inactiv
certain
rang
concentr
addit
effect
inactiv
obviou
increas
novel
prepar
strategi
one
time
success
establish
properti
protein
assess
sdspage
esiquadm
malditofm
ntermin
sequenc
well
western
blot
fast
highli
effici
methodolog
enabl
us
focu
energi
subsequ
research
branch
mpeg
lysnh
kda
use
modifi
protein
serial
pegyl
one
assess
gradient
sdspage
malditofm
modifi
possess
onem
twomer
threemer
pegbound
chain
modifi
obtain
onem
twomer
pegbound
chain
pegyl
conjug
preserv
moder
activ
jar
choriocarcinoma
cell
furthermor
pegyl
protein
show
antitumor
antiviru
activ
well
immunogen
decreas
compar
unmodifi
counterpart
sum
pegyl
may
offer
possibl
way
clinic
applic
potenti
therapeut
agent
nevertheless
fulfil
requir
use
drug
meet
challeng
includ
reduct
immunogen
greatest
extent
retent
suffici
activ
extens
halflif
period
develop
variou
form
pegrip
work
begin
use
clinic
therapeut
protein
must
fulfil
requir
describ
previous
pegyl
reduc
immunogen
retain
certain
biolog
activ
rip
lot
work
decreas
immunogen
extend
halflif
period
intern
journal
nanomedicin
intern
peerreview
journal
focus
applic
nanotechnolog
diagnost
therapeut
drug
deliveri
system
throughout
biomed
field
journal
index
pubm
central
medlin
ca
current
medicin
journal
citat
reportssci
edit
embas
scopu
elsevi
bibliograph
databas
manuscript
manag
system
complet
onlin
includ
quick
fair
peerreview
system
easi
use
visit
http
wwwdovepresscom
testimonialsphp
read
real
quot
publish
author
intern
journal
nanomedicin
futur
work
concern
pack
rip
nanomateri
target
drug
low
releas
